Polish pharmaceuticals market Clinic Pharma - our expert scientists and researches in Poland assist you through pharmaceuticals and medical aspects of drugs registration in Poland: pre-registration and post-registration including medical, pharmaceutical aspects of medicinal products and medical translation into polish.

• Piggy-back studies
• Pharmacoeconomic analysis
• HTA Reports
• Measuring outcomes (clinical, patient - based)
• Cost-effectiveness, cost-benefit and cost-utility analysis
• Economic analysis alongside clinical trials
• Reimbursement

Measuring outcomes

The essential part of each pharmacoeconomic (PE) analysis is the measurement of clinical outcomes. We will help you in these measurements whether it is analysis of particular trial or meta-analysis of several trials. We will help you with interpretation of these outcomes whether they are related to efficacy or effectiveness of drugs.

We will help you with many problems associated with relative effectiveness. We have recently introduced the consideration of patients perceptions as this measure sometimes referred to as health - related quality of life is an important outcome in addition to the life-years gained.

Cost-effectiveness, cost-benefit and cost-utility analysis

We will help you with the writing and final format of your analysis. Needless to say, the important mission of your analysis is to convince decision makers to your product or the programme. Most of the PE analysis is written in the hermetic language that forms a barrier to a layman administrator. However, he is the one making decision about your product. We will help you to write or to translate your analysis into language understandable to the decision maker.

Economic evaluation alongside clinical trials

We will help you to identify the economic outcomes most relevant to your analysis. We then can proceed to the "piggy-back" study collecting economic outcomes alongside clinical trials. This can be done retrospectively or prospectively. If the sample size of particular clinical trial is inadequate we will help you to create appropriate models. Finally, our team will assist you with statistical testing of your piggy-back trial.

Reimbursement

We have a long experience with reimbursement. We will help you with identifying real and potential (under registration) competitors. We will assist you in the analysis of the market. We will do our best to prepare you for price negotiations. Finally we will help you with filing the application for reimbursement.

Our service include: performing clinical studies with economical outcomes (piggy-back trials), cost-effectiveness analyses, cost-benefit analyses, applications for reimbursement.

Our experience: numerous cost-effective analyses some published and presented at international meetings^x.

The ideas mentioned above are extremely important at the stage of planning. Once the project is well-planned the chances for success are high. Success means value: excellent plan is a success as well as each step, even the smallest one, on the way to the big goal. We think meticulously on each move - this is how we build and how we consider value.

Achieving a goal is of paramount importance. It does not matter whether you are starting your business or "you are old" in the business and you know how to do it. When you are starting you need a success to survive, when you are "old" you cannot afford a failure. Throughout the life of your medicinal product, especially at its delivery, and to help its survival our service is of real value. Try us to know how profitable could be our assistance.

Expert Voice

During last two months there is a growing pressure on the budget to increase the GNP share for the health care. All the parties present at several meetings, e.g. "Koalicja dla Zdrowia", "Reimbursement", "Rynek Zdrowia" and others argue that this share should be increased by 2%. Ministry declares (this is not a new declaration, some may thing about déja vu phenomenon)... read more